Sarepta therapeutics announces second quarter 2023 financial results and recent corporate developments

Cambridge, mass.--(business wire)--sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter 2023. “with a positive advisory committee vote followed by the approval of elevidys in june, this quarter marks an historic milestone in the treatment of duchenne muscular dystrophy. the launch of elevidys is off to a great start, with our first reimbursed infusion today, ahead of plan. in addition to mak.
SRPT Ratings Summary
SRPT Quant Ranking